<DOC>
	<DOCNO>NCT00090285</DOCNO>
	<brief_summary>This study evaluate investigational vaccine follow objective : demonstrate vaccine well tolerate young men ; demonstrate vaccine reduces incidence external genital lesion ( Condylomata acuminata [ anogenital wart ] , penile/perianal/perineal intraepithelial neoplasia [ PIN ] , penile , perianal , perineal cancer ) young men ; demonstrate vaccine reduces incidence anal intraepithelial neoplasia ( AIN ) anal cancer men sex men ( MSM ) ; demonstrate vaccine reduces incidence Human Papilloma Virus ( HPV ) infection young men .</brief_summary>
	<brief_title>An Investigational Study Gardasil™ ( qHPV , V501 ) Vaccine Reducing Incidence Anogenital Warts Young Men ( V501-020 )</brief_title>
	<detailed_description>The base study ( V501-020 ) encompass Day 1 Month 7 , time participant receive randomly assign Gardasil™ ( qHPV vaccine ) placebo Day 1 , Month 2 , Month 6 . Base study follow-up continued Month 36 . The base study extend protocol V501-020-10 Extension 1 ( EXT1 ) . Participants receive placebo participant receive 1 dose qHPV vaccine base study offer complete 3-dose qHPV vaccine regimen ( administered EXT1 Day 1 , Month 2 Month 6 ) . Participants receive 2 dos qHPV vaccine base study offer single additional dose qHPV vaccine ( administered EXT1 Day 1 ) . Participants follow EXT1 Month 7 . A second extension study , V501-020-21 ( EXT2 ) , estimate long-term safety effectiveness qHPV vaccine period 10 year follow initial enrollment base study . Subjects receive least one dose qHPV vaccine either base study EXT1 eligible enroll EXT2 .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male age 16 year 23 year 364 day . For MSM substudy , age 16 year 26 year 364 day . No clinical evidence genital lesion suggest sexuallytransmitted disease , history anogenital wart Additional criterion discuss physician Concurrently enrol clinical study involve collection genital specimens History know prior vaccination HPV vaccine Received inactivate vaccine within 14 day live virus vaccine within 21 day prior enrollment History severe allergic reaction require medical intervention Received immune globulin bloodderived product within 6 month prior first study injection History splenectomy , immune disorder , receive immunosuppressive Immunocompromised diagnosed HIV infection Known thrombocytopenia coagulation disorder would contraindicate intramuscular injection History recent ongoing alcohol drug abuse</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>anogenital wart</keyword>
</DOC>